Smith & Nephew (NYSE:SNN) Rating Lowered to Neutral at UBS Group

UBS Group cut shares of Smith & Nephew (NYSE:SNN) from a buy rating to a neutral rating in a research note issued to investors on Wednesday morning, Marketbeat reports.

SNN has been the subject of a number of other reports. StockNews.com raised shares of Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 26th. Canaccord Genuity Group reissued a “hold” rating and set a $27.00 price target on shares of Smith & Nephew in a research report on Wednesday, February 26th. Four research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Smith & Nephew has a consensus rating of “Hold” and an average target price of $27.00.

Smith & Nephew Trading Up 1.3 %

Shares of NYSE SNN opened at $28.59 on Wednesday. Smith & Nephew has a 1 year low of $23.65 and a 1 year high of $31.72. The stock has a market cap of $12.50 billion, a P/E ratio of 13.23, a price-to-earnings-growth ratio of 1.26 and a beta of 0.83. The firm has a 50-day moving average of $26.35 and a 200 day moving average of $27.18. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.51 and a quick ratio of 1.11.

Smith & Nephew Increases Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Friday, March 28th will be paid a dividend of $0.447 per share. This is a positive change from Smith & Nephew’s previous semi-annual dividend of $0.29. This represents a yield of 2.5%. The ex-dividend date is Friday, March 28th. Smith & Nephew’s dividend payout ratio (DPR) is currently 41.20%.

Institutional Trading of Smith & Nephew

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Vident Advisory LLC increased its stake in Smith & Nephew by 158.8% during the 4th quarter. Vident Advisory LLC now owns 21,564 shares of the medical equipment provider’s stock valued at $530,000 after purchasing an additional 13,232 shares in the last quarter. Wexford Capital LP bought a new stake in shares of Smith & Nephew in the fourth quarter worth approximately $541,000. Point72 Asset Management L.P. bought a new stake in shares of Smith & Nephew in the fourth quarter worth approximately $6,132,000. Quantinno Capital Management LP grew its stake in shares of Smith & Nephew by 83.8% in the fourth quarter. Quantinno Capital Management LP now owns 97,818 shares of the medical equipment provider’s stock worth $2,404,000 after acquiring an additional 44,592 shares during the period. Finally, J. Goldman & Co LP bought a new stake in shares of Smith & Nephew in the fourth quarter worth approximately $47,700,000. 25.64% of the stock is currently owned by institutional investors.

About Smith & Nephew

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.